title: Wavelength-dependent effect of tetra(m-hydroxyphenyl)chlorin for photodynamic therapy in an 'early' squamous cell carcinoma model.
abstract: The purpose of the present study was to correlate the wavelength of the irradiation source with the phototoxic activity of tetra(m-hydroxyphenyl)chlorin (mTHPC) in healthy and neoplastic mucosae. The hamster tumour model for early squamous cell carcinoma was used in these experiments. In vitro and in vivo studies have shown that mTHPC absorbs significantly at 652 nm (1, 2). This wavelength is used currently in clinical mTHPC photodynamic therapy (PDT) trials. In order to study the wavelength dependence of the phototoxic effect on normal and tumour tissues, irradiation tests were performed 4 days after injection of 0.5mg kg(-1) mTHPC. An argon-ion pumped dye laser was used as the light source. The light dose of 12 J cm(-2) was delivered at a light dose rate of 150 mW cm(-2). The wavelength was varied between 642.5 and 665 nm at 2.5-nm increments. The PDT damage was evaluated in serial Haematoxylin and Eosin stained sections using a tissue-damage scale. Light between 647.5 and 652.5 nm induced the highest damage to both the healthy and tumour mucosae. At wavelengths equal to or below 645 nm, and equal to or above 655 nm, tissue damage decreased. Wavelengths below 642 nm and above 660 nm did not induce any visible tissue damage. These results suggest that the in vivo optimal wavelength range for PDT with mTHPC is between 647 and 652 nm. This information is essential for selecting an appropriate light source.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, CHUV Hospital, BH 10, 1011, Lausanne, Switzerland.
authors.forename: S A
authors.initials: SA
authors.lastname: Blant
authors.forename: J F
authors.initials: JF
authors.lastname: Theumann
authors.forename: M
authors.initials: M
authors.lastname: Forrer
authors.forename: G
authors.initials: G
authors.lastname: Wagnières
authors.forename: H
authors.initials: H
authors.lastname: Van Den Bergh
authors.forename: P
authors.initials: P
authors.lastname: Monnier
references.citation: Semin Surg Oncol. 1995 Sep-Oct;11(5):355-9
references.pmid: 7569557
references.citation: J Clin Laser Med Surg. 1996 Oct;14(5):281-7
references.pmid: 9612194
references.citation: Photochem Photobiol. 1994 Oct;60(4):383-7
references.pmid: 7991665
references.citation: Photochem Photobiol. 1996 Dec;64(6):963-8
references.pmid: 8972639
references.citation: Lasers Surg Med. 1989;9(4):405-21
references.pmid: 2761336
references.citation: J Invest Dermatol. 1995 Nov;105(5):672-7
references.pmid: 7594642
references.citation: Phys Med Biol. 1992 Jun;37(6):1219-30
references.pmid: 1626022
references.citation: Pathol Res Pract. 1989 Jun;184(6):567-76
references.pmid: 2476791
references.citation: Int J Exp Pathol. 1996 Feb;77(1):7-14
references.pmid: 8664146
references.citation: Cancer Detect Prev. 1991;15(4):291-301
references.pmid: 1794136
references.citation: J Laryngol Otol. 1993 Dec;107(12):1140-5
references.pmid: 8289004
references.citation: Chest. 1992 Nov;102(5):1319-22
references.pmid: 1424843
references.citation: Int J Cancer. 1995 Oct 9;63(2):198-204
references.pmid: 7591204
references.citation: Dermatology. 1992;184(3):202-4
references.pmid: 1382731
references.citation: J Photochem Photobiol B. 1994 Aug;24(3):195-9
references.pmid: 7646616
references.citation: Cancer Res. 1990 Jul 15;50(14):4441-5
references.pmid: 1694722
references.citation: Int J Cancer. 1994 Jun 15;57(6):883-8
references.pmid: 8206681
references.citation: J Histochem Cytochem. 1955 May;3(3):170-95
references.pmid: 14381606
references.citation: Appl Opt. 1996 Apr 1;35(10):1756-66
references.pmid: 21085299
references.citation: J Dent Res. 1954 Apr;33(2):253-62
references.pmid: 13152263
references.citation: Anticancer Drugs. 1992 Apr;3(2):139-42
references.pmid: 1525391
references.citation: J Natl Cancer Inst. 1993 Mar 17;85(6):443-56
references.pmid: 8445672